CDD Vault will support Voronoi's collaborative research on Kinase Inhibitor and TPD
INCHEON, South Korea and SAN FRANCISCO, Aug. 23, 2019 /PRNewswire/ -- Voronoi, a drug discovery and development biotech company in Korea announced today that it has, after an extensive evaluation process, selected CDD Vault as its platform of choice to manage its drug discovery data and collaborative projects. Voronoi's chemistry and biology data, including chemical structures and assay data will be stored, managed and analyzed in CDD Vault developed by Collaborative Drug Discovery.
Voronoi through its divisions Voronoi Bio and B2S Bio has implemented a new streamlined drug discovery process. It includes molecular modeling and Target Protein Degrader (TPD) technology to identify new targets as well as new drug candidates. Voronoi's research efforts are focused on Alzheimer's disease, stroke, head trauma, glioblastoma, pancreatic cancer and kidney cancer. Key to the success of Voronoi are the collaborations that the company has established with entities such as Korea Biotechnology Institute, Korea Brain Research Institute, and National Cancer Center.
CDD Vault is a hosted platform for managing chemistry and biology data. It has features for Activity and Registration, Assay Management, Inventory, Electronic Laboratory Notebook for Chemistry and Biology and Visualization and Reporting. The ergonomic design of CDD Vault makes it easy to use for all scientists including chemists, pharmacologists and biologists, and scientists can be productive in a short period of time. CDD Vault has been designed to manage local projects as well as largely distributed research networks in a secure way.
"We are honored that Voronoi has chosen CDD Vault as their discovery data management platform of choice," said Dr. Barry Bunin, CEO of Collaborative Drug Discovery, Inc. "Our mission is to help maximize the output of our customers' discovery efforts. To that end, we strive to provide the best informatics tools required by Voronoi and similar research organizations."
"We have selected CDD Vault because we needed a flexible platform to manage our drug discovery programs and collaborations," affirmed Prof. Hyunseok Kim. "We needed a solution to manage chemical compounds, assay data and an Electronic Laboratory Notebook to record our experiments, and CDD Vault fulfills all our requirements. CDD Vault enables us to collate data from multiple sources and extract the maximum information from them."
Voronoi is the leading biotech in Korea. Lead by world class scientists, Voronoi has the largest medicinal chemistry team in the country. The company is focused on developing kinase inhibitors. It has ten programs in progress in the area of oncology, inflammatory and neurodegenerative diseases. Voronoi has a large research capability and it has developed strong partnerships with renowned institutions around unique and interesting new chemical entities with potential to be a drug. For more information visit https://voronoi.io/ko/
About Collaborative Drug Discovery, Inc.
CDD's flagship product, 'CDD Vault®', is used to manage chemical registration, structure activity relationships (SAR) and securely scale collaborations. CDD Vault® is a hosted database solution for secure management and sharing of biological and chemical data. It lets you intuitively organize chemical structures and biological study data and collaborate with internal and/or external partners through an easy-to-use web interface. Available modules include Activity & Registration, Visualization, Inventory and ELN. For more information visit www.collaborativedrug.com
Mariana Vaschetto, PhD
Collaborative Drug Discovery, Inc.